Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|November 19, 2026

Simtra BioPharma Solutions Opens $250 Million Building H to Expand Sterile Injectable Capacity in Bloomington

Listen
0:00 / 0:00

Key Takeaways

  • Building H expands sterile fill-finish breadth with prefilled syringe, vial, and lyophilization capacity, positioning the Bloomington site for more complex injectable programs.
  • A network-wide investment plan includes >$125 million in Halle/Westfalen and >$150 million at the Bloomington Park Campus, aiming for 18 filling lines by 2027.
SHOW MORE

Simtra BioPharma Solutions has opened Building H, a 153,000-square-foot, $250 million-plus expansion in Bloomington, Indiana, that adds prefilled syringe, vial, and lyophilization capacity. The CDMO plans to grow from 11 to 18 filling lines across its US and European network by 2027.

Simtra BioPharma Solutions, a contract development and manufacturing organization (CDMO) focused exclusively on sterile injectables, opened Building H on November 9, 2026, a more than $250 million expansion of its manufacturing campus in Bloomington, Indiana.¹ The 153,000-square-foot facility adds prefilled syringe, vial, and lyophilization capabilities, expanding the range of sterile injectable products Simtra can support.¹

“Our customers are planning years ahead, and they need manufacturing partners that can do the same.” Ray Guidotti, chief operating officer, Simtra BioPharma Solutions

Indiana Governor Mike Braun and Bloomington Mayor Kerry Thomson joined company leaders, employees, and economic development officials at the ribbon-cutting ceremony.¹ Simtra expects the expansion to create hundreds of jobs in Bloomington.¹

“Building H represents much more than additional manufacturing capacity. It is an important milestone in the growth strategy we are executing across Simtra,” said Franco Negron, chief executive officer of Simtra BioPharma Solutions.¹ “We are investing in the capacity, technology and infrastructure our customers need to develop and manufacture increasingly complex sterile injectable medicines.”¹

How does Building H fit into Simtra’s broader expansion?

Building H is one piece of a multisite growth plan. Simtra has invested more than $125 million to expand manufacturing capacity in Halle/Westfalen, Germany, and has made an initial investment of more than $150 million at its new Bloomington Park Campus.¹ Across its US and European network, the company plans to grow from 11 filling lines to 18 by 2027.¹

The opening follows earlier steps at the Bloomington site. In October 2025, Simtra said it had added a flexible clinical line for prefilled syringes and liquid and lyophilized vials and was building a new production facility to house three isolator commercial-scale filling lines.² In a sponsored BioPharm International® video, Bo Watkins, senior vice president of sales and business management at Simtra, described the Bloomington expansions, including new syringe and vial lines and the site’s first high-potency filling line.

“Building H gives us significant new capacity in Bloomington today to go along with our expansion in Halle, while investment in our new Park campus creates additional options for the future,” said Ray Guidotti, chief operating officer of Simtra.¹ “Together, these investments give customers greater flexibility in where and how they manufacture and provide a foundation that can scale as their programs grow.”¹

Why is sterile fill-finish capacity in demand?

Growth in biologics, biosimilars, and GLP-1 therapies is driving demand for sterile drug products, and CDMOs are investing in fill-finish, lyophilization, inspection, and packaging capacity to keep pace.³ Prefilled syringes are a large part of that demand; one forecast projects the global prefilled syringe market will grow from $9.4 billion in 2026 to $20.3 billion by 2035.³

Sponsors are also outsourcing more of this work. A Research and Markets report cited increased outsourcing to CDMOs as an important driver of fill-finish market growth, reflecting sponsors’ need for specialized sterile manufacturing expertise and flexible production capacity.⁴ Grand View Research projects that the global sterile injectables CDMO market will grow from $41.6 billion in 2026 to $87.3 billion by 2033.⁴

That shift is changing what sponsors expect from manufacturing partners. In a BioPharm International video interview at BIO 2026, Kasper Øland, vice president of sales execution at Samsung Biologics, said, “Rather than treating CDMOs as supply chain vendors, companies increasingly expect a CDMO to function as an extension of their own operational team to ensure greater predictability, transparency, and timeline flexibility.”

What happens next?

With Building H open, Simtra’s next milestones are the continued buildout in Halle and at the Bloomington Park Campus as it works toward 18 filling lines by 2027.¹ The company has not disclosed when the new Building H lines will begin commercial production or which customer programs they will support.

“The facility combines advanced manufacturing technology with robust infrastructure to support the consistent, reliable supply of vital injectable products to our customers and their patients,” said Pat Adams, vice president of expansion operations at Simtra.¹

References

  1. Simtra BioPharma Solutions celebrates opening of $250+ million Bloomington manufacturing expansion. News release. Simtra BioPharma Solutions; November 9, 2026. Accessed November 19, 2026.
  2. Simtra BioPharma Solutions expands global manufacturing footprint to advance the future of sterile injectables. News release. Simtra BioPharma Solutions; October 27, 2025. Accessed November 19, 2026.
  3. Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity. BioSpace. Published August 3, 2026. Accessed November 19, 2026.
  4. Biologics, GLP-1s driving evolution of fill-finish manufacturing. Pharma Manufacturing. Published August 6, 2026. Accessed November 19, 2026.

Related to this article